Immunicom, Inc. is a privately held biotechnology company with a new technology platform for immuno-oncology and inflammatory disorders. Immunicom’s highly selective Immunopheresis® blood and/or plasma constituent removal technology is designed to effectively treat a wide variety of cancers and immunological disorders with a safer side-effect profile than conventional treatments. Immunicom’s lead product, the LW-02 Column, previously received FDA Breakthrough Device designation in 2018 for Stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in patients with advanced, refractory, metastatic triple negative breast cancer (TNBC). LW-02 Column Immunopheresis is currently being evaluated in several globally based oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA, with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.
